According to the Centers for Disease Control and Prevention (CDC), 6 million people aged 18 years or older have prediabetes in the United States and 26.4 million people aged 65 years or older (48.8%) have prediabetes.
Growing Prevalence of Diabetic Foot Ulcer
In 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents.
The rising incidence of diabetes worldwide is one of the major drivers of the diabetic foot ulcer treatment market. According to the International Diabetes Federation, the number of people with diabetes worldwide is expected to increase from 463 million in 2019 to 700 million by 2045. Diabetes is a leading cause of foot ulcers, which require proper treatment and management to avoid complications such as amputations. The increasing geriatric population is another driver of the diabetic foot ulcer treatment market. Older adults are more likely to develop diabetes and are at a higher risk of developing diabetic foot ulcers. According to the World Health Organization, the global population aged 65 years and older is expected to double from 703 million in 2019 to 1.5 billion in 2050, which is expected to increase the demand for diabetic foot ulcer treatment. The growing trend of home healthcare is another driver of the diabetic foot ulcer treatment market. Many patients prefer to receive care at home rather than in hospitals or clinics, which is expected to increase the demand for homecare settings for diabetic foot ulcer treatment. Rising healthcare expenditure, especially in emerging economies, is driving the demand for diabetic foot ulcer treatment. Governments and private organizations are investing in improving healthcare infrastructure and promoting awareness about diabetes and its complications, which is expected to increase the demand for diabetic foot ulcer treatment.
Technological Advancement
For instance, in July 2019, AVITA Medical, g global regenerative medicine company, announced favourable results from an open label feasibility study of the RECELL Autologous Cell Harvesting Device for the treatment of Diabetic Foot Ulcers.
Recent Development
- In January 2019, UPM launched a new advanced wound care product in the European market and FibDex is the product for wound dressing, created from wood based nanofibrillar cellulose to receive regulatory approval and to be awarded with a CE mark.
- Launched in 2020 by Urgo Medical, UrgoStart Contact is a bioactive wound dressing that contains a protease-modulating matrix. The product is designed to promote wound healing and reduce the risk of infection in diabetic foot ulcers.
- Launched in 2019 by Covalon Technologies Ltd, Agilus HealX is an antimicrobial wound dressing that incorporates silver and iodine to prevent infection in diabetic foot ulcers. The product is designed to be used in conjunction with standard wound care protocols.
- Launched in 2018 by Podimetrics, the Remote Temperature Monitoring System is a telemedicine platform that uses temperature sensors to detect early signs of diabetic foot ulcers. The system allows healthcare providers to remotely monitor patients and intervene before the ulcer becomes severe.
Download Free Sample Report
Market Segmentation
Market Players
3M Company, Medtronic Plc, ConvaTec, Inc., Coloplast Corporation, Smith & Nephew Plc, B Braun Melsungen AG, Medline Industries, Inc., Organogenesis, Inc., Molnlycke Health Care AB, Acelity L.P., Inc.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · By Treatment · By Ulcer Treatment · By End User |
Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Turkey; Egypt; |
Key companies profiled | 3M Company, Medtronic Plc, ConvaTec, Inc., Coloplast Corporation, Smith & Nephew Plc, B Braun Melsungen AG, Medline Industries, Inc., Organogenesis, Inc., Molnlycke Health Care AB, Acelity L.P., Inc. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |